Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company that develops and commercializes innovative products aimed at managing chronic pain while addressing the challenges of prescription drug abuse. The company utilizes its patented DETERx platform technology to create abuse-deterrent formulations that maintain the extended-release and safety profiles of medications despite potential misuse methods such as chewing or crushing. Collegium's product lineup includes Xtampza ER, an extended-release oral formulation of oxycodone designed to deter abuse, and Nucynta, which features both extended-release and immediate-release formulations of tapentadol for the treatment of severe pain, including conditions like diabetic neuropathy. Headquartered in Stoughton, Massachusetts, Collegium Pharmaceutical focuses on improving patient outcomes while mitigating the risks associated with opioid medications.